Details of the Drug Reposition

General Information of This Drug (ID: DMUWXEB)

Drug Name
QPI-1007   DMUWXEB
Synonyms SiCASP2; SiRNA therapy (caspase-2, ocular injury), Quark Pharmaceuticals
Drug Type
siRNA drug

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ischemic optic neuropathy DISOFUFW 9C40.4 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2/3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Glaucoma/ocular hypertension DISLBXBY 9C61 Phase 2/3 [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02341560) Phase II/III, Randomized, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION). U.S. National Institutes of Health.